Ninlaro Could Replace First-line Velcade in Older Myeloma Patients, Study Suggests
Older multiple myeloma patients who are unable to receive a stem cell transplant could receive Ninlaro (ixazomib) as part of their first line-therapy instead…
Myeloma
Dendritic Cell Vaccine in Immunotherapy Triple Combo Seen to Boost Immune Response to Myeloma in Early Study
A triple combination treatment — dendritic cell vaccination plus Revlimid (lenalidomide) and an anti-PD-1 checkpoint inhibitor — led to stronger anti-tumor immune responses against myeloma…
Ninlaro Maintenance Therapy Fares Well in Phase 3 Multiple Myeloma Trial
Takeda‘s proteasome inhibitor Ninlaro (ixazomib) prevents multiple myeloma from progressing or returning when given as a maintenance therapy to patients who responded to first-line therapy…
Early Relapse in Multiple Myeloma Linked to Greater Economic Burden in US
Multiple myeloma patients whose cancer progresses early after first-line therapy have a greater economic burden compared to those whose disease progresses later, a recent study…
Twice‐weekly Ninlaro Combo Improves Outcomes in Newly Diagnosed Myeloma Patients, Trial Shows
Twice‐weekly Ninlaro (ixazomib) plus Revlimid (lenalidomide) and dexamethasone can improve long-term outcomes in patients with newly diagnosed multiple…
Kyprolis Label to Include Positive Data of Aspire Trial in Advanced Multiple Myeloma Patients
Prescribing information for Kyprolis (carfilzomib) in the U.S. will now include positive survival data from the ASPIRE Phase 3 clinical trial, which found treatment significantly…
Advanced Blood Sample Analysis Could Be Better Than Bone Marrow Biopsies, Study Shows
Genetic analysis of multiple myeloma DNA from two different sources present in blood samples provides researchers equally relevant cancer information as more invasive bone marrow…
Empliciti Triple Combo Delays Disease Progression in Advanced Myeloma Patients, Phase 2 Trial Data Show
Adding Empliciti (elotuzumab) to a combination of Pomalyst (pomalidomide) and dexamethasone significantly delays disease worsening or death in myeloma patients who failed to respond to previous treatment,…
Trial of Virus Combo to Treat Multiple Myeloma Adding Keytruda to Mix for Patient Group
A Phase 1b trial testing a combination of Reolysin (pelareorep), Velcade (bortezomib) and dexamethasone in multiple myeloma patients who failed to respond to previous therapy…
Mutations in Noncoding Regions of Human Genome Also Cause Cancer, Study Shows
While the best described cancer mutations are in regions that provide instructions to make proteins, most mutations actually happen in the noncoding regions of our…
Recent Posts
- Treatment before surgery slows PDAC disease progression: Study
- Scientists discover tissue differences in brain cancer in children
- Elahere approved in EU as treatment for ovarian cancer
- Survival better with Blenrep combo than Darzalex for R/R myeloma
- Aucatzyl, a cell therapy, approved in US for adults with advanced B-ALL